Fuan Pharmaceutical's subsidiary received the notification of approval for the sodium benzosulfonate chemical raw material drug market application.

Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Chongqing Boson Pharmaceutical Co., Ltd. (referred to as "Boson Pharmaceutical"), recently received a notification of approval for the market application of sodium benzylpenicillin chemical raw materials issued by the National Medical Products Administration. Sodium benzylpenicillin is mainly used for various infections caused by penicillin-resistant Staphylococcus aureus, including sepsis, respiratory tract infections, meningitis, soft tissue infections, etc. It can also be used for mixed infections caused by pyogenic streptococci or pneumococci and penicillin-resistant Staphylococcus aureus. The approval of the above-mentioned raw material product for the market will be able to be used in domestic marketed formulations, further enriching the product line of the subsidiary companies.